この記事を読む

ラムシルマブ+エルロチニブ出番はあるか?

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a rand…

この記事を読む

PD-L1超高発現の生存データ:90%がカットオフ?

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression. Aguilar…

この記事を読む

ニボルマブの4年生存率

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled anal…

この記事を読む

EGFR遺伝子変異は胸水検体だけで正しいか

Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with ade…

この記事を読む

終末期における胸部緩和照射

Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis. Fraser I et al. Lung …

この記事を読む

HPDに関係する遺伝子変異

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lu…

この記事を読む

シンプルな栄養指標と免疫治療の奏効予測

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immun…

この記事を読む

TKIと殺細胞性抗がん剤併用の再現性

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. Noronha V et al. J …

この記事を読む

免疫療法単剤、腫瘍マーカー低下も早期効果指標となる

Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated a…

この記事を読む

維持療法に適しているのはベバシズマブ、ペメトレキセド、それとも両者?

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: …